Eli Lilly wins a quick OK for new sarcoma drug olaratumab
Eli Lilly has won an accelerated FDA approval of its soft tissue sarcoma drug olaratumab with set of positive results from a small mid-stage study. Lilly plans to sell the drug as Lartruvo to a slice of patients for frontline use — the first such approval to come along in decades for this disease.
The drug targets PDGF receptors which cause tumor growth.
The agency’s green light comes just a month after the EU’s CHMP offered a positive opinion about a similar move in Europe, setting up a likely transAtlantic sweep for Lilly, which has been pouring resources into its oncology pipeline in recent years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
